Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 5:11:616062.
doi: 10.3389/fneur.2020.616062. eCollection 2020.

Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease

Affiliations

Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease

Francesco Cavallieri et al. Front Neurol. .

Abstract

Importance: The effects of dopaminergic treatment on speech in patients with Parkinson's disease (PD) are often mixed and unclear. The aim of this study was to better elucidate those discrepancies. Methods: Full retrospective data from advanced PD patients before and after an acute levodopa challenge were collected. Acoustic analysis of spontaneous monologue and sustained phonation including several quantitative parameters [i.e., maximum phonation time (MPT); shimmer local dB] as well as the Unified Parkinson's Disease Rating Scale (UPDRS) (total scores, subscores, and items) and the Clinical Dyskinesia Rating Scale (CDRS) were performed in both the defined-OFF and -ON conditions. The primary outcome was the changes of speech parameters after levodopa intake. Secondary outcomes included the analysis of possible correlations of motor features and levodopa-induced dyskinesia (LID) with acoustic speech parameters. Statistical analysis included paired t-test between the ON and OFF data (calculated separately for male and female subgroups) and Pearson correlation between speech and motor data. Results: In 50 PD patients (male: 32; female: 18), levodopa significantly increased the MPT of sustained phonation in female patients (p < 0.01). In the OFF-state, the UPDRS part-III speech item negatively correlated with MPT (p = 0.02), whereas in the ON-state, it correlated positively with the shimmer local dB (p = 0.01), an expression of poorer voice quality. The total CDRS score and axial subscores strongly correlated with the ON-state shimmer local dB (p = 0.01 and p < 0.01, respectively). Conclusions: Our findings emphasize that levodopa has a poor effect on speech acoustic parameters. The intensity and location of LID negatively influenced speech quality.

Keywords: Parkinson's disease; acoustic analysis; dysarthria; dyskinesias; levodopa; speech.

PubMed Disclaimer

Conflict of interest statement

FC received personal fees from Zambon outside the submitted work. EMo has received honoraria from Abbott, Medtronic, and Newronika for consulting and lecturing; she has received an educational grant from Boston Scientific. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Correlation between intensity and location of LID and acoustic speech parameters. (A) Significant positive correlation between Clinical Dyskinesia Rating Scale (CDRS) total score (x-axis) and shimmer local DB (y-axis) in the ON condition. (B) Significant positive correlation between axial CDRS subscore (x-axis) and noise-to-harmonics ratio (y-axis) in the ON condition. (C) Statistically positive correlation between axial CDRS subscore (x-axis) and shimmer local DB (y-axis) in the ON condition. These results highlight that patients with higher intensity of levodopa-induced dyskinesia, particularly in the axial region, had a poorer voice quality.

References

    1. Chenausky K, Macauslan J, Goldhor R. Acoustic analysis of PD speech. Parkinsons Dis. (2011) 2011:435232 10.4061/2011/435232 - DOI - PMC - PubMed
    1. Skodda S, Grönheit W, Mancinelli N, Schlegel U. Progression of voice and speech impairment in the course of Parkinson's disease: a longitudinal study. Parkinsons Dis. (2013) 2013:389195. 10.1155/2013/389195 - DOI - PMC - PubMed
    1. Darley L, Aronson AE, Brown JR. Clusters of diagnostic patterns of dysarthria. J Speech Hear Res. (1969) 12:253 10.1044/jshr.1202.246 - DOI - PubMed
    1. Fabbri M, Guimarães I, Cardoso R, Coelho M, Guedes LC, Rosa MM, et al. . Speech and voice response to a levodopa challenge in late-stage Parkinson's disease. Front Neurol. (2017) 8:432. 10.3389/fneur.2017.00432 - DOI - PMC - PubMed
    1. Brabenec L, Mekyska J, Galaz Z, Rektorova I. Speech disorders in Parkinson's disease: early diagnostics and effects of medication and brain stimulation. J Neural Transm. (2017) 124:303–34. 10.1007/s00702-017-1676-0 - DOI - PubMed

LinkOut - more resources